Abstract
Remifentanil has been well known to cause much more significant bradycardia and hypotension as compared with other opioids. However, the underlying mechanism is still poorly understood. The present study hypothesized that remifentanil led to bradycardia and hypotension with distinct mechanisms and aimed to test this hypothesis. Testing the hypothesis would broaden our understanding the underlying mechanism of remifentanil and may provide some guidance in the use of remifentanil clinically. Mean arterial pressure and heart rate were measured before and at the indicated time after drug treatment in the anesthetized rabbits. In the vagotomy group, bilateral vagus in the neck was exposed and one section of the vagus severed respectively. Remifentanil caused slight but significant bradycardia immediately which recovered entirely within one minute. On the other hand, bolus injection of remifentanil led to severe hypotension which sustained for more than five minutes. Bilateral vagotomy could delay the recovery of remifentanil-mediated bradycardia but did not affect remifentanil-evoked hypotension significantly. Pretreatment with naloxone, a non-specific opioid receptor antagonist could entirely prevent the remifentanil-mediated hypotension but only partially reversed remifentanil-mediated bradycardia. Remifentanil induces bradycardia and hypotension with distinct physiological and biochemical mechanisms. Remifentanil-induced bradycardia is mediated by opioid receptor-dependent and -independent pathways; however, remifentanil-induced hypotension is only through opioid receptor-dependent pathway. Key words: Remifentanil, bradycardia, hypotension, opioid receptor, hemodynamic effect.
Highlights
Remifentanil is a potent opioid of the 4-anilidopiperidine type with a similar pharmacodynamic property to other opioids
Vagus denervation by bilateral vagotomy did not prevent the hemodynamic changes in response to remifentanil administration
The present study showed that remifentanil decreased heart rate (HR) mildly and shortly
Summary
Remifentanil is a potent opioid of the 4-anilidopiperidine type with a similar pharmacodynamic property to other opioids. As compared with other opioids, remfentanil has a unique pharmacokinetic characteristic with a very short half time and widely used in clinical anesthesia (Beers and Camporesi, 2004). It has been widely known that remifentanil has more severe hemodynamic consequences compared with other opioids (Elliott et al, 2000; Kazmaier et al, 2000; Wang et al, 1999). Using echocardiography, a previous study suggested that the decreased blood pressure was caused by the reduction of heart rate (HR) (Chanavaz et al, 2005). Another study showed that remifentanil decreased mean arterial pressure (MAP) in the patients with artificial heart
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
